Chemopreventive of breast cancer with selective estrogen receptor modulators: Views from broadly diverse focus groups of women with elevated risk for breast cancer

Psycho-Oncology

Volumn 10, Issue 6, 2001, Pages 521-533

  Cyrus David, M S ^a   Strom, S S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CELL; CANCER GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; FEAR; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MEDICAL DECISION MAKING; PATIENT ATTITUDE; RISK BENEFIT ANALYSIS; RISK FACTOR; BREAST TUMOR; INFORMATION PROCESSING; PSYCHOLOGICAL ASPECT; RISK; SCIENCE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; FOCUS GROUPS; HUMAN; KNOWLEDGE; MIDDLE AGE; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN;

EID: 0034747074     PISSN: 10579249     EISSN: None     Source Type: Journal    
DOI: 10.1002/pon.547     Document Type: Article

References (39)

1. The use of mammography by survivors of breast cancer
2. Recruiting black men to a clinical trial to evaluate prostate cancer screening - Detroit, Michigan
3. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program
4. Antineoplastic agents
5. Recent trends in the U.S. breast cancer incidence, survival, and mortality rates
6. The Tuskegee Syphilis Study
7. Chemoprevention of breast cancer with tamoxifen
8. Phase III clinical trial of tamoxifen as a chemopreventinve for breast cancer - The United States National Cancer Institute experience
9. Psychological responses to tumor markers
10. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
11. Weighing the risk and benefits of tamoxifen treatment for preventing breast cancer
12. Cancer statistics
13. Epidemiology of breast cancer
14. Breast cancer
15. Data management and analysis methods
16. The health belief model
17. Final report on the 'Tuskegee Syphilis Study'
18. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial
19. Population risk, actual risk, perceived risk, and cancer control: A discussion
20. Coming to terms with advanced breast cancer: Black women's narratives from eastern North Carolina
21. Compliance with mammography guideliness: Physician recommendation and patient adherence
22. Recent trends for breast cancer in women and the believe of early detection: An update
23. Chemoprevention of breast cancer in the older patient
24. Home care requirements for children and adolescents with cancer
25. Potential role of tamoxifen in prevention of breast cancer
26. Controlling quantitative data: Understanding teachers' value perspectives on a sex education project
27. Breast cancer screening and African American women: Fear, fatalism, and silence
28. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial
29. Involving family members in cancer care: Focus group considerations of patients and oncological providers
30. Chemoprevention: Pre-clinical drug development paradigms for chemopreventives
31. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women
32. Some pharmaceutical drugs
33. Cancer and poverty: Breaking the cycle
34. Antiestrogens
35. Use of focus groups with rural women of lower socioeconomic status
36. Reverse targeting of preventive care due to lack of health insurance
37. Raloxifene, retinoids, and lavender: 'Me too' tamoxifen alternatives under study